CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

What You Should Know Bioanalytical Method Validation

What You Should Know Bioanalytical...

Optimizing Manufacturing for Clinical Development with N-SIDE Production App

Optimizing Manufacturing for Clinical...

MediciNova Secures Patent for MN-166 and Riluzole

MediciNova Secures Patent for MN-166...

The Future of Biosimilars and Biobetters

The Future of Biosimilars and Biobetters

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

What You Should Know Bioanalytical Method Validation

What You Should Know Bioanalytical...

Optimizing Manufacturing for Clinical Development with N-SIDE Production App

Optimizing Manufacturing for Clinical...

MediciNova Secures Patent for MN-166 and Riluzole

MediciNova Secures Patent for MN-166...

The Future of Biosimilars and Biobetters

The Future of Biosimilars and Biobetters

Forbion Announces its New General Partner

Life Sciences Review | Wednesday, June 16, 2021
Tweet

Bos led a team of twenty-one investment professionals at M Ventures, which invested 400 million euros in over 50 portfolio companies ranging from biotech to life sciences tools to IT, with investment activities ranging from seed to cross-over and IPO.


FREMONT, CA: Forbion, a leading European life sciences venture capital firm, announced the addition of Jasper Bos, Ph.D., a former Merck executive, as General Partner for the firm's Growth Fund. Bos was Senior Vice President and Managing Director of M Ventures, the venture arm of pharmaceutical major Merck, before joining Forbions' Naarden headquarters in 2009. He led a team of twenty-one investment professionals at M Ventures, which invested 400 million euros in over 50 portfolio companies ranging from biotech to life sciences tools to IT, with investment activities ranging from seed to cross-over and IPO.


"In light of the recent, sizable final close, at the EUR 360 million hard cap of our Forbion Growth Opportunities Fund I, we are pleased to have a seasoned life sciences investment professional like Jasper joining our growing team. Jasper has overseen four companies through their IPO process, and has vast experience with pharma spin-outs and prominent licensing deals involving diverse stakeholders from big-pharma to leading academic institutions. 


His scientific and financial experience will be instrumental as we continue implementing our strategy which is to enable the most innovative companies bring new impactful treatments and therapies to market," explained Sander Slootweg, Managing Partner, Forbion.


Commenting on his appointment as General Partner, Jasper Bos added, "I am excited to be joining Forbion, in my view one of the leading investment firms in the life sciences space, and to actively contribute to deploying their Growth Opportunities Fund and thus help to grow the market for late-stage European biotech investing in Europe. I look forward to working with the Forbion team, and I am confident that my track record in the industry will be complementary to theirs, especially when it comes to creating pharma spin outs."


Bos has previously worked with the Netherlands Vaccine Institute, the Dutch National Institute of Public Health, and private equity firms. He graduated from the University of Groningen in the Netherlands with a doctorate in pharmacy.


Weekly Brief

loading
Top 10 Bioanalytical Services Companies in Europe - 2021
Top 5 Bioanalytical Service Companies In Uk – 2021
Top 5 Emerging Bioanalytical Services Companies in UK and Europe - 2021
Top 10 Bioanalytical Services Companies in Europe - 2021
Top 5 Bioanalytical Service Companies In Uk – 2021
Top 5 Emerging Bioanalytical Services Companies in UK and Europe - 2021
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/forbion-announces-its-new-general-partner-nwid-399.html